Citius Oncology, Inc. (CTOR) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Citius Oncology, Inc. stock (CTOR) is currently trading at $0.58. Citius Oncology, Inc. PS ratio (Price-to-Sales) is 14.39. Analyst consensus price target for CTOR is $6.00. WallStSmart rates CTOR as Sell.
- CTOR PE ratio analysis and historical PE chart
- CTOR PS ratio (Price-to-Sales) history and trend
- CTOR intrinsic value — DCF, Graham Number, EPV models
- CTOR stock price prediction 2025 2026 2027 2028 2029 2030
- CTOR fair value vs current price
- CTOR insider transactions and insider buying
- Is CTOR undervalued or overvalued?
- Citius Oncology, Inc. financial analysis — revenue, earnings, cash flow
- CTOR Piotroski F-Score and Altman Z-Score
- CTOR analyst price target and Smart Rating
Citius Oncology, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Citius Oncology, Inc. (CTOR) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Citius Oncology, Inc. (CTOR) Key Strengths (1)
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
Citius Oncology, Inc. (CTOR) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Very expensive at 14.4x annual revenue
Very low institutional interest at 8.16%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Citius Oncology, Inc. (CTOR) Detailed Analysis Report
Overall Assessment
This company scores 19/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 1 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 1.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (0.96) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (14.39) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -47.40%, Operating Margin at -133.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -47.40% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CTOR Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CTOR's Price-to-Sales ratio of 14.39x trades 29% below its historical average of 20.25x (0th percentile). The current valuation is 41% below its historical high of 24.4x set in Feb 2026, and 0% above its historical low of 14.39x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~24.4x as trailing revenue scaled faster than the stock price.
Compare CTOR with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Citius Oncology, Inc. (CTOR) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Citius Oncology, Inc. operates as a stable business with moderate growth and solid fundamentals. Revenue reached 4M with 0% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 26% of revenue (1M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -7M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 3.04, so expect amplified moves relative to the broader market.
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Citius Oncology, Inc..
Bottom Line
Citius Oncology, Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Citius Oncology, Inc.(CTOR)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Citius Oncology, Inc. is a clinical-stage biopharmaceutical firm committed to the development of groundbreaking cancer therapies tailored for underserved populations. The company boasts a promising pipeline that utilizes proprietary technologies to create innovative treatments aimed at various cancer indications, enhancing both efficacy and safety. Through strategic partnerships and a dedication to thorough clinical research, Citius Oncology is well-positioned for significant growth as it navigates crucial clinical trial phases and regulatory pathways, with the ultimate goal of improving patient outcomes in oncology.